TIE1抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using TIE1 mouse mAb against HepG2 cell lysate.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human liver cancer tissues using TIE1 mouse mAb with DAB staining.    

  
  

The TIE1 (tyrosine kinase with immunoglobulin-like and EGF-like domains 1) antibody is a research tool designed to detect and study the TIE1 receptor, a transmembrane tyrosine kinase predominantly expressed in endothelial cells. First identified in the early 1990s, TIE1 plays a critical role in vascular development and angiogenesis, though its precise signaling mechanisms remain less understood compared to its homolog TIE2 (TEK). Structurally, TIE1 contains extracellular immunoglobulin-like domains, EGF-like repeats, and fibronectin type III motifs, but lacks a known high-affinity ligand, distinguishing it from TIE2. which binds angiopoietins.

Research suggests TIE1 regulates endothelial cell stability, vascular remodeling, and blood vessel maturation, often through interactions with TIE2 or modulation of angiopoietin-TIE2 signaling. Knockout studies in mice reveal embryonic lethality due to hemorrhaging and defective vascular integrity, underscoring its importance in developmental angiogenesis. In pathological contexts, TIE1 is implicated in tumor angiogenesis, atherosclerosis, and inflammatory diseases, making it a potential therapeutic target.

TIE1 antibodies are widely used in techniques like Western blot, immunohistochemistry, and flow cytometry to analyze protein expression, localization, and signaling pathways. Recent studies also explore its role in endothelial-to-mesenchymal transition (EndMT) and vascular leakage. Despite progress, questions persist regarding its ligand-independent activation and context-dependent functions, driving ongoing research to elucidate its full biological significance.